Introduction
Alzheimer’s disease has long been treated with medications that manage symptoms without changing the disease itself. That landscape shifted with the arrival of two FDA-approved amyloid-targeting therapies: lecanemab (brand name Leqembi) and donanemab (brand name Kisunla). These drugs represent a major step forward in dementia care, but they are not miracle cures. Understanding how they work, what they cost, and how insurance handles them is essential for patients and families navigating this new treatment era.
This guide breaks down the science, the clinical results, the financial reality, and the practical steps needed to access these therapies in the United States. You will get clear, actionable information to help you make informed decisions about early-stage Alzheimer’s care.
How These New Drugs Actually Work
Both lecanemab and donanemab belong to a class of medications called monoclonal antibodies. These are laboratory-designed proteins that travel through the bloodstream to find and bind to specific targets. In Alzheimer’s disease, the target is amyloid-beta, a sticky protein that clumps together to form plaques in the brain. Over time, these plaques disrupt communication between nerve cells and trigger inflammation that damages brain tissue.
Targeting Amyloid Plaques
Traditional Alzheimer’s medications, like donepezil or memantine, work on brain chemicals such as acetylcholine or glutamate. They help with memory and thinking for a while but do not touch the underlying disease process. The new drugs take a different approach. They attach to amyloid plaques and help the immune system clear them out. By reducing plaque buildup, these therapies aim to slow the rate of cognitive decline.
How They Compare to Older Medications
Older drugs typically provide modest symptom relief for six to twelve months. The new amyloid-modifying therapies are designed to change the disease trajectory. They require intravenous (IV) infusions, usually given every two to four weeks at a certified infusion center or hospital. Unlike pill-based treatments, these drugs target the biology of Alzheimer’s directly, which is why they are reserved for patients with confirmed early-stage disease.
Realistic Expectations and Safety Considerations
It is important to separate marketing hype from clinical reality. These drugs do not reverse memory loss, restore lost skills, or stop Alzheimer’s completely. They slow progression. Understanding the actual numbers and safety requirements helps set a grounded treatment plan.
What the Clinical Trials Showed
In large Phase 3 trials, lecanemab slowed cognitive and functional decline by approximately 27 percent over 18 months compared to a placebo. Donanemab showed a similar pattern, with a 35 percent slowing of decline in patients with early symptoms and confirmed amyloid plaques. These percentages may sound small, but in neurodegenerative disease, they translate to meaningful time. Patients often experience slower worsening of daily tasks like managing finances, driving, and recognizing familiar people.
Importantly, these benefits only appear in people with mild cognitive impairment or mild dementia caused by Alzheimer’s. The drugs are not approved for moderate or severe stages, nor for other types of dementia like vascular or Lewy body disease.
Understanding ARIA and MRI Monitoring
The most notable side effect is called amyloid-related imaging abnormalities, or ARIA. ARIA involves temporary brain swelling or tiny microbleeds that show up on MRI scans. Most people experience no symptoms, but some report headaches, confusion, dizziness, or vision changes. Serious cases are rare but require immediate medical attention.
To catch ARIA early, the FDA requires regular brain imaging. Patients typically undergo MRI scans before starting treatment, then again after the first few doses, and every three to four months throughout therapy. If ARIA appears, doctors may pause the infusion, adjust the dose, or stop treatment depending on severity. This monitoring schedule is a standard part of the treatment protocol and must be factored into time and travel planning.
Costs and Insurance Coverage in the US
The list price for these therapies is high, but the actual out-of-pocket cost depends heavily on insurance type, prior authorization status, and manufacturer assistance programs. Knowing how the US payment system handles these drugs prevents surprise bills and helps families plan ahead.
Medicare and the ADDT Model
Medicare covers both lecanemab and donanemab under the Alzheimer’s Disease Diagnostic and Treatment (ADDT) model expansion. This coverage applies when two conditions are met: the patient has early-stage Alzheimer’s, and the diagnosis is confirmed by an amyloid PET scan or cerebrospinal fluid test. Medicare Part B covers the infusion and monitoring costs. Patients typically pay 20 percent of the approved amount after meeting their Part B deductible.
The drug itself carries a list price of roughly $26,500 per year for lecanemab and $24,000 per year for donanemab. Medicare does not pay the full list price. Instead, it reimburses based on negotiated rates, and the manufacturer often provides a discount or rebate that lowers the actual cost. Many patients with supplemental Medigap plans or Medicare Advantage plans pay little to nothing out of pocket for the medication itself.
Navigating Private Insurance
Private insurers vary widely in their coverage policies. Most require prior authorization, which means your neurologist must submit medical records, cognitive test results, and amyloid confirmation before the drug is approved. Some plans use step therapy, requiring you to try older medications first, though this is less common for FDA-approved disease-modifying treatments.
Out-of-pocket costs for commercially insured patients can range from a few hundred dollars to several thousand dollars per year, depending on your plan’s specialty drug tier and annual maximums. Both manufacturers offer patient assistance programs that cap monthly payments and help with co-pays. Infusion center fees, lab work, and MRI scans are billed separately and should be verified with your insurance provider before starting treatment.
Who Qualifies and What to Do Next
Accessing these therapies requires a clear diagnostic pathway. You cannot start treatment based on symptoms alone. The first step is a comprehensive evaluation by a neurologist or memory clinic specialist. This evaluation includes cognitive testing, brain imaging, and blood work to rule out other causes of memory loss.
If early Alzheimer’s is suspected, your doctor will order an amyloid confirmation test. This is usually a PET scan or a spinal tap to measure amyloid and tau proteins in the cerebrospinal fluid. Once confirmed, your care team will review your medical history, check for bleeding disorders or blood thinner use, and schedule baseline MRIs. If you qualify, the infusion schedule begins, and a dedicated care coordinator usually helps with insurance paperwork, appointment tracking, and side effect monitoring.
Medication is only one piece of the puzzle. Lifestyle factors remain critical. Regular aerobic exercise, a Mediterranean-style diet, quality sleep, and social engagement all support brain health. Cognitive rehabilitation therapy and caregiver support groups provide practical tools for daily living. Combining approved therapies with these proven strategies offers the most balanced approach to long-term brain health.
Conclusion
The arrival of lecanemab and donanemab marks a turning point in Alzheimer’s care. These drugs do not cure the disease, but they offer a scientifically validated way to slow progression in early-stage patients. The treatment requires commitment, including regular infusions, routine MRI scans, and careful insurance navigation. Costs are substantial, but Medicare coverage and manufacturer assistance programs make the therapies accessible to many eligible patients.
If you or a loved one are experiencing early memory changes, do not wait. Early diagnosis is the key to accessing these treatments while they can still make a difference. Work with a neurologist, confirm amyloid status, verify insurance benefits, and build a care plan that blends medication, monitoring, and lifestyle support. Alzheimer’s management has evolved, and staying informed puts you in control of the next steps.